USP6NL

USP6NL (RN-tre) is a TBC-domain Rab-GTPase-activating protein that controls membrane trafficking by inactivating specific Rab GTPases, and through this activity it tunes receptor signaling, focal adhesion dynamics, and Golgi architecture (PMID:12399475, PMID:24239119, PMID:41401861). Structurally, it engages its substrate Rab43 through a bipartite recognition mechanism in which an N-terminal TBC subdomain catalytically remodels the Rab Switch regions via an RQ-dual-finger arrangement while a C-terminal subdomain enforces substrate specificity; this analysis defined Rab19 as an additional substrate and showed that disease-associated mutations impair GAP activity to produce aberrant Golgi architecture and endocytic trafficking (PMID:41401861). USP6NL acts as a GAP for Rab5 and Rab43 (PMID:24239119). It is recruited to activated EGFR through a constitutive, Eps8-independent association with the Grb2 adaptor, where it inhibits Rab5-dependent EGFR endocytosis; in breast cancer cells with high USP6NL this delays EGFR/AKT downregulation, stabilizes GLUT1 at the plasma membrane, and sustains aerobic glycolysis and proliferation (PMID:12399475, PMID:29691252). At focal adhesions and associated Rab5-positive vesicles, USP6NL selectively blocks endocytosis of β1 (but not β3) integrins in a GAP- and Rab5-dependent manner, delaying focal adhesion turnover and impairing chemotactic migration (PMID:24239119). Its GAP activity is cell-cycle regulated through CDK-dependent mitotic phosphorylation that is reversed by the hCdc14A dual-specificity phosphatase (PMID:17371873), and in Drosophila it additionally links the trafficking machinery to Rho1–ROCK–myosin II contractility partly independently of its GAP activity (PMID:32816624).

1. 1996 Medium

   Establishing USP6NL's molecular identity and first protein partner addressed what this newly cloned protein is and how it might act, revealing an Eps8-binding protein with transforming potential and a conserved TrH domain.

   Evidence cDNA cloning, chromosomal mapping, in vitro/in vivo SH3-binding assays, and NIH3T3 transformation assay

   PMID:8700515 PMID:8700527

   Open questions at the time

   • No enzymatic activity or substrate defined at this stage
   • Mechanism of transformation by the truncation mutant unresolved
   • Cellular pathway context unknown
2. 2002 High

   Identifying a constitutive Grb2 association resolved how USP6NL is targeted to its site of action, showing EGF-driven Grb2-dependent recruitment to EGFR that blocks receptor internalization.

   Evidence Reciprocal Co-IP in vitro and in vivo, Grb2 binding-deficient mutant, overexpression/dominant-negative assays, fluorescence microscopy

   PMID:12399475

   Open questions at the time

   • Did not define the Rab substrate underlying the endocytic block
   • Physiological versus overexpression-dependent effects not separated
3. 2007 High

   Demonstrating cell-cycle phosphorylation and hCdc14A-mediated dephosphorylation answered how USP6NL's catalytic activity is temporally regulated, linking its GAP function to mitotic control.

   Evidence Substrate-trapping with catalytically inactive hCdc14A, in vitro phosphatase assay, CDK phosphorylation assay, cell cycle synchronization, Co-IP

   PMID:17371873

   Open questions at the time

   • Specific phosphosites and their individual functional consequences not fully mapped
   • Trafficking consequence of mitotic regulation not directly tested
4. 2013 High

   Defining USP6NL as a Rab5/Rab43 GAP at focal adhesions established its substrate specificity and a concrete cellular role, showing selective inhibition of β1-integrin endocytosis controls focal adhesion turnover and migration.

   Evidence Live-cell imaging, siRNA loss-of-function, GAP-dead rescue, integrin endocytosis and chemotaxis assays

   PMID:24239119

   Open questions at the time

   • Basis for β1 versus β3 integrin selectivity not structurally explained
   • Whether Grb2 recruitment operates at focal adhesions not addressed
5. 2018 High

   Connecting USP6NL to a EGFR→AKT→GLUT1 metabolic axis explained how its endocytic control feeds tumor metabolism, identifying it as a driver of aerobic glycolysis and proliferation in USP6NL-high breast cancer.

   Evidence siRNA knockdown, EGFR endocytosis assay, phospho-AKT western blot, GLUT1 membrane fractionation, glucose uptake and proliferation assays

   PMID:29691252

   Open questions at the time

   • Direct GAP-dependence of the metabolic phenotype not isolated with a GAP-dead mutant
   • In vivo tumor relevance not established here
6. 2020 Medium

   An RNAi screen in Drosophila revealed a GAP-partially-independent link between USP6NL and Rho1–ROCK–myosin II contractility, expanding its role beyond canonical Rab inactivation.

   Evidence RNAi in S2 cells, phosphomyosin immunostaining, GAP-dead mutant, constitutively active Rho/Rok rescue, contractility and actin flow assays

   PMID:32816624

   Open questions at the time

   • GAP-independent mechanism on Rho1 not molecularly defined
   • Conservation of this function in mammalian cells not confirmed
   • Single lab, ortholog-based
7. 2025 High

   The RN-Tre–Rab43 crystal structure resolved the long-open question of how USP6NL achieves catalysis and substrate selectivity, defining a bipartite RQ-dual-finger mechanism and linking disease mutations to impaired GAP activity and Golgi/endocytic defects.

   Evidence X-ray crystallography of the RN-Tre–Rab43 complex, mutational analysis, in vitro GAP assays, Golgi morphology and trafficking assays

   PMID:41401861

   Open questions at the time

   • Structural basis for Rab5 recognition not directly solved
   • Specific disease and inheritance pattern not detailed in this analysis

• How USP6NL's distinct functional contexts — EGFR/Grb2 signaling, focal-adhesion integrin trafficking, mitotic phosphoregulation, Golgi maintenance, and Rho1-contractility crosstalk — are coordinated by a single GAP within one cell remains unresolved.
• No unified model integrating its multiple substrates and localizations
• Mechanism switching GAP-dependent versus GAP-independent functions unknown
• In vivo physiological hierarchy of these roles undetermined